IntelliGenome Receives FDA Breakthrough Device Designation for CRISPR-TB Blood Test

HOUSTON, Jan. 21, 2025 /PRNewswire/ -- IntelliGenome, an innovative molecular diagnostic solutions provider, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its CRISPR-Tuberculosis (TB) Blood Test. This test is the...